What East Sunshine does

East Sunshine Group is a privately held Chinese high-tech conglomerate founded in 1997 in Dongguan, Guangdong, operating across three industrial verticals: electronic new materials, biopharmaceuticals, and health and wellness. The group holds two publicly listed subsidiaries — Guangdong East Sunshine Technology Holdings (600673.SH on the Shanghai A-share market) and East Sunshine Pharmaceutical (06887.HK on the Hong Kong Stock Exchange) — and reports total assets exceeding 90 billion RMB, with cumulative taxes paid of more than 23 billion RMB since inception. Operations span seven domestic production bases (Dongguan, Shaoguan, Yichang, Dongyang, Ulanqab, Zunyi, and Linzhi) plus 15 overseas sales branches across Japan, the United States, Germany, Australia, the United Kingdom, South Korea, Indonesia, France, and India, with overseas markets contributing roughly 15% of total sales.

The group's technology foundation rests on its 2005-established research institute, which has grown to 1,700+ R&D personnel (including 100+ PhDs, 1,000+ Masters, and 20+ foreign experts) and 3,500+ patent applications (1,500+ international). Its most distinctive proprietary technology is industrial-scale ecological cultivation of Cordyceps sinensis — a globally first — supported by a ~400,000 square meter cultivation base yielding 60+ tons annually, two consumer brands ('East Sunshine Fresh Cordyceps' and 'East Sunshine Buzhi'), and a State Administration of Traditional Chinese Medicine key laboratory designation. The electronic materials business is currently being reorganized around a new core industrial chain spanning power components, new chemical materials, liquid cooling technology, and AI computing power infrastructure.

East Sunshine operates through five coordinated sales platforms staffed by 4,000+ dedicated sales personnel, targeting B2B enterprise customers in electronics and pharmaceuticals (hospitals, pharmacies, distributors, API manufacturers) and B2C consumers for cordyceps-based health products via Tmall and retail channels. Recent strategic actions — including the December 2025 acquisition of Suzhou Datu Thermal Control for high-power chip liquid cooling, the August 2025 acquisition of Yichang Changjiang Pharmaceutical, and the April 2026 groundbreaking of an advanced computing power industrial base with Qinhui Data — indicate active repositioning of the materials and pharmaceutical core toward AI-era infrastructure adjacencies.

Name

East Sunshine

Legal name

东阳光集团 (East Sunshine Group)

Website

https://hec.cn

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

East Sunshine Group is a privately held Chinese high-tech conglomerate operating in electronic new materials, biopharmaceuticals, and cordyceps-based health products, with two listed subsidiaries (600673.SH and 06887.HK), seven domestic production bases, 30,000+ employees, and an expanding pivot toward AI computing infrastructure and liquid cooling technology.

Ownership category

akta.pro rank

Product category

Diversified Industrial Manufacturing (Electronic Materials, Pharmaceuticals, Health Products)

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Mushroom Production (111411)

SIC

Chemicals & Allied Products (2800), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Chlor-Alkali & Derivatives (IMAEAAAC)

akta.pro secondary industry

Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Electronic new materials
• Biopharmaceuticals manufacturing
• Cordyceps health supplements
• Liquid cooling technology
• Aluminum foil production

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices17 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. 电子新材料 (Electronic New Materials): Manufacturing and sales of aluminum foil, electronic components, chemical new materials, and energy materials. Listed on A-share market as East Sunshine (600673.SH).
2. 生物医药 (Biopharmaceuticals): R&D, production and sales of pharmaceuticals. Listed on Hong Kong Stock Exchange as East Sunshine Pharma (06887.HK). Focus on infection, chronic disease, and oncology treatment areas.
3. 健康养生 (Health and Wellness): Cordyceps-based health products under two brands: premium 'East Sunshine Fresh Cordyceps' (东阳光鲜虫草) and mass-market 'East Sunshine Buzhi' (东阳光补己). Sold through Tmall e-commerce and retail channels.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels4 records

Core offering

East Sunshine Group manufactures and sells electronic new materials (aluminum foil, electronic components, chemical new materials, energy materials, and liquid cooling solutions for data centers and AI servers), develops and commercializes biopharmaceuticals for infection, chronic disease, and oncology treatment areas, and produces cordyceps-based health supplements under the East Sunshine Fresh Cordyceps (premium) and East Sunshine Buzhi (mass-market) brands. The group operates seven production bases across China and exports through 15 overseas branches, with total assets exceeding 90 billion RMB and over 30,000 employees.

Product overview

East Sunshine (东阳光) is a large-scale high-tech股份制 enterprise operating three main industry sectors: electronic new materials, biopharmaceuticals, and health/lifestyle products. The company has two listed entities - Dongyangguang (600673.SH) in electronic materials and Dongyangguang Pharmaceutical (01558.HK, 06887.HK) in pharmaceuticals - with seven production bases across China. In electronic materials, the company is transforming toward AI computing power and liquid cooling technology. In pharmaceuticals, it focuses on infectious diseases, chronic conditions, and oncology with integrated R&D, manufacturing, and sales. In health products, it operates the world's first large-scale cordyceps ecological cultivation with two consumer brands: premium 'Dongyangguang Fresh Cordyceps' and value-oriented 'Dongyangguang Buchi'.

Differentiator

Problem solved

Functional benefit

Brands

• 东阳光鲜虫草 (East Sunshine Fresh Cordyceps): High-end cordyceps sinensis brand positioned as benchmark quality product for premium health supplements.
• 东阳光补己 (East Sunshine Buji)
• 东阳光药 (East Sunshine Pharmaceutical)
• 东阳光科技 (East Sunshine Technology)

Quantifiable outcome

• Annual cordyceps production capacity exceeding 60 tons from 400,000+ sqm ecological cultivation base
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• 秦淮数据 (Qinhui Data)coreStrategic or Co-development Partner · 3 April 2026East Sunshine and Qinhui Data jointly established the Advanced Computing Power Industry Base project in Yichang, Yidu City. The project represents East Sunshine's strategic entry into AI computing infrastructure, combining East Sunshine's industrial capabilities with Qinhui Data's data center expertise.
• 大图热控 (Datu Thermal Control / Suzhou Datu Thermal Control Technology Co., Ltd.)coreStrategic or Co-development Partner · 5 December 2025East Sunshine's liquid cooling subsidiary (Zhejiang East Sunshine Liquid Cooling Technology Co., Ltd.) completed acquisition framework agreement with the actual controller of Datu Thermal Control. Datu Thermal Control is an industry leader in high-power chip liquid cooling technology. This acquisition strengthens East Sunshine's strategic position in liquid cooling and high-performance heat dissipation for data centers and AI servers.

Scale indicators13 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Sino Biopharmaceutical: Hong Kong-listed Chinese pharmaceutical conglomerate with diversified therapeutic-area coverage and growing innovation pipeline. Comparable to East Sunshine Pharma in listed-pharma scale, R&D breadth, and therapeutic-area diversification.
• Jiangsu Hengrui Medicine: China's largest innovative pharmaceutical company, listed on Shanghai A-share, with strong R&D in oncology and chronic disease. Comparable to East Sunshine Pharma in pharmaceutical innovation pipeline and internationalization ambitions.
• Fosun International: Diversified Chinese conglomerate with operations spanning pharmaceuticals (Fosun Pharma), health products, and industrial/consumer businesses. Comparable as a privately controlled group with multiple listed subsidiaries operating across unrelated verticals.
• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical company with strong oncology, chronic disease, and API operations. Comparable to East Sunshine Pharma in therapeutic focus, R&D investment, and internationalization strategy.
• Yunnan Baiyao Group: Chinese TCM and health-products conglomerate with proprietary botanical formulations and integrated manufacturing. Directly comparable to East Sunshine's cordyceps health-products business and pharmaceutical distribution platform.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed TCM manufacturer and distributor focused on classic Chinese medicine formulations. Comparable to East Sunshine Pharma in TCM pharmaceutical R&D, manufacturing, and distribution.

Broad incumbents

• Tongwei Co., Ltd. Major Chinese electronic materials and energy materials manufacturer (silicon, solar, agriculture). Comparable to East Sunshine Technology in electronic new materials, chemicals, and energy materials manufacturing scale.
• CATL (Contemporary Amperex Technology): China's leading battery and energy materials company with adjacent electronic materials capabilities. Comparable to East Sunshine Technology's energy materials and chemical materials businesses in scale and advanced manufacturing.
• Shanghai Pharmaceuticals Holding: Dual-listed (Shanghai and Hong Kong) Chinese pharmaceutical distributor and manufacturer with both innovative drugs and API businesses. Comparable to East Sunshine Pharma in dual-exchange listing and integrated pharma distribution.

Regional players

• Walvax Biotechnology: China-based biopharmaceutical company focused on biological products including vaccines and biosimilars. Comparable to East Sunshine Pharma in biopharmaceutical R&D and Chinese-market commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about East Sunshine